Alpha Tau to Present Pooled Pancreatic Cancer Data at Prestigious ASCO Annual Meeting
DRTS has more than doubled off its 52-week low of $2.5.
Summary
Alpha Tau Medical announced that an abstract showcasing combined safety and efficacy data from three Alpha DaRT pancreatic cancer studies has been accepted for presentation at the highly prestigious ASCO Annual Meeting.
Key Events · Product Development and Regulatory · DRTS
-
ASCO Abstract Acceptance
An abstract detailing combined safety and efficacy results from three Alpha DaRT pancreatic cancer studies has been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
-
Pooled Clinical Data
The abstract presents a pooled analysis of safety and efficacy data from 58 patients across three prospective clinical studies evaluating Alpha DaRT treatment for locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).
-
Upcoming Publication
The abstract is scheduled to be published on the ASCO conference website on May 21, 2026, at 5:00 PM ET.
Analysis · DRTS · Industrial Applications And Services
This announcement signifies a major validation for Alpha Tau's Alpha DaRT technology in treating pancreatic cancer, a notoriously difficult-to-treat malignancy. Acceptance at the ASCO Annual Meeting, the world's largest oncology conference, for combined safety and efficacy data from three clinical studies, lends significant scientific credibility and visibility to their program. This milestone builds on recent positive news, such as the initiation of the ACAPELLA trial, and underscores the growing maturity of their clinical evidence base, which could attract further investment and partnership opportunities.
At the time of this filing, DRTS was trading at $8.25 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $712M. The 52-week trading range was $2.50 to $8.60. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.